Current Infectious Disease Reports

, Volume 2, Issue 4, pp 352–357 | Cite as

Cryptococcal meningitis in HIV-infected patients

  • William G. Powderly


Cryptococcosis is a fungal infection that is potentially deadly for and common among AIDS patients, in the United States and worldwide. Subacute meningitis and meningoencephalitis are typical, clinically. This article will review relevant aspects of cryptococcal meningitis in AIDS, focusing on the most recent information pertaining to pathogenesis, epidemiology, clinical syndromes, and treatment of this devastating disease.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Kwon-Chung KJ, Rhodes JC: Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans. Infect Immun 1986, 51:218–223.PubMedGoogle Scholar
  2. 2.
    Pettoello-Mantovani M, Casadevall A, Kollmann TR, et al.: Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans. Lancet 1992, 339:21–23.PubMedCrossRefGoogle Scholar
  3. 3.
    Lee SC, Casadevall A: Polysaccharide antigen in brain tissue of AIDS patients with cryptococcal meningitis. Clin Infect Dis 1996, 23:194–195.PubMedGoogle Scholar
  4. 4.
    Kwon-Chung KJ, Kozel TR, Edman JC, et al.: Recent advances in biology and immunology of Cryptococcus neoformans. J Med Vet Mycol 1992; 30:133–142.PubMedGoogle Scholar
  5. 5.
    Levitz SM: The Ecology of Cryptococcus neoformans and the Epidemiology of Cryptococcosis. Rev Infect Dis 1991, 13:1163–1169.PubMedGoogle Scholar
  6. 6.
    Speed B, Dunt D: Clinical and Host Differences Between Infections with the Two Varieties of Cryptococcus neoformans. Clin Infect Dis 1995, 21:28–34.PubMedGoogle Scholar
  7. 7.
    Rinaldi MG, Drutz DJ, Howell A, et al.: Serotypes of Cryptococcus neoformans in patients with AIDS. J Infect Dis 1986, 153:642.PubMedGoogle Scholar
  8. 8.
    Perfect JR, Granger DL, Durack DT: Effects of antifungal agents and gamma interferon on macrophage cytotoxicity for fungi and tumor cells. J Infect Dis 1987, 156:316–323.PubMedGoogle Scholar
  9. 9.
    Huffnagle GB, Lipscomb MF: Cells and cytokines in pulmonary cryptococcosis. Res Immunol 1998, 149:387–396.PubMedCrossRefGoogle Scholar
  10. 10.
    Lortholary O, Improvisi L, Rayhane N, et al.: Cytokine profiles of AIDS patients are similar to those of mice with disseminated Cryptococcus neoformans infection. Infect Immun 1999, 67:6314–6320.PubMedGoogle Scholar
  11. 11.
    Casadevall A: Antibody immunity and invasive fungal infections. Infect Immun 1995, 63:4211–4218.PubMedGoogle Scholar
  12. 12.
    Fleuridor R, Lyles RH, Pirofski L: Quantitative and qualitative differences in the serum antibody profiles of human immunodeficiency virus-infected persons with and without Cryptococcus neoformans meningitis. J Infect Dis. 1999, 180:1526–1535.PubMedCrossRefGoogle Scholar
  13. 13.
    Currie BP, Casadevall A: Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin Infect Dis 1994, 19:1029–1033.PubMedGoogle Scholar
  14. 14.
    Hajjeh RA, Conn LA, Stephens DS, et al.: Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group. J Infect Dis 1999, 179:449–454.PubMedCrossRefGoogle Scholar
  15. 15.
    Mocroft A, Sabin CA, Youle M, et al.: Changes in AIDS-defining illnesses in a London Clinic, 1987–1998. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 21:401–407.Google Scholar
  16. 16.
    Garcia-Hermoso D, Janbon G, Dromer F: Epidemiological evidence for dormant Cryptococcus neoformans infection. J Clin Microbiol 1999, 37:3204–3209.PubMedGoogle Scholar
  17. 17.
    Abadi J, Pirofski LA: Antibodies reactive with the cryptococcal capsular polysaccharide glucuronoxylomannan are present in sera from children with and without human immunodeficiency virus infection. J Infect Dis 1999, 180:915–919.PubMedCrossRefGoogle Scholar
  18. 18.
    Driver JA, Saunders CA, Heinze-Lacey B, et al.: Cryptococcal pneumonia in AIDS: is cryptococcal meningitis preceded by clinically recognizable pneumonia? J Acquir Immune Defic Syndr Hum Retrovirol 1995, 9:168–171.PubMedGoogle Scholar
  19. 19.
    Feldmeser M, Harris C, Reichberg S, Khan S, Casadevall A. Serum cryptococcal antigen in patients with AIDS. Clin Infect Dis 1996, 23:827–830.Google Scholar
  20. 20.
    Powderly WG, Cloud GA, Dismukes WE, et al.: Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis. Clin Infect Dis 1994, 18:789–792.PubMedGoogle Scholar
  21. 21.
    Van der Horst CM, Saag NS, Cloud GA, et al.: Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997, 337:15–21.PubMedCrossRefGoogle Scholar
  22. 22.
    De Lalla F, Pellizzer G, Vaglia A, et al.: Amphotericin B as primary therapy for cryptococcosis in AIDS patients: reliability of relatively high doses administered over a relatively short period. Clin Infect Dis 1995, 20:263–266.PubMedGoogle Scholar
  23. 23.
    Chuck SL, Sande MA: Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med 1989, 321:794–799.PubMedCrossRefGoogle Scholar
  24. 24.
    Powderly WG. Cryptococcal meningitis and AIDS. Clin Infect Dis 1993, 17:837–842.PubMedGoogle Scholar
  25. 25.
    Saag MS, Cloud GA, Graybill, JR, et al.: A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis. 1999, 28:291–296. This randomized comparison of fluconazole and itraconazole as suppressive therapy was stopped early because of the striking superiority of fluconazole. An interesting analysis suggested that the use of flucytosine in the initial treatment regimen was associated with a lower risk of relapse. Although considerable caution is needed in interpreting these data (there may be considerable selection bias), they are consistent with the hypothesis that more aggressive initial therapy (including rapid sterilization of the CSF) improves long-term outcome (see also reference 27).PubMedGoogle Scholar
  26. 26.
    Saag MS, Powderly WG, Cloud GA, et al.: Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992, 326:83–89.PubMedCrossRefGoogle Scholar
  27. 27.
    Robinson PA, Bauer M, Leal MA, et al.: Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999, 28:82–92. This retrospective analysis of 236 patients, all treated at the same center, reported 12% acute mortality and 26% mortality at 10 weeks. High CSF cryptococcal antigen titers, low CD4 count and low serum albumin levels were predictive of a poor outcome. Higher doses of amphotericin were associated with more rapid sterilization of the CSF.PubMedGoogle Scholar
  28. 28.
    Larsen RA, Bozzette SA, Jones BE, et al.: Fluconazole combined with flucytosine for the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994, 19:741–747.PubMedGoogle Scholar
  29. 29.
    Sharkey PK, Graybill JR, Johnson ES, et al.: Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996, 22:315–321.PubMedGoogle Scholar
  30. 30.
    Leenders AC, Reiss P, Portegies P, et al.: Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997, 11:1463–1471.PubMedCrossRefGoogle Scholar
  31. 31.
    Hamill RJ, Sobel J, el-Sadr W, et al.: Randomized double blind trial of Ambisome (liposomal amphotericin B) and amphotericin B in acute cryptococcal meningitis in AIDS patients. [abstract]. In Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, 1999.Google Scholar
  32. 32.
    Denning DW, Armstrong RW, Lewis BH, Stevens DA: Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome. Am J Med 1991, 91:267–272.PubMedCrossRefGoogle Scholar
  33. 33.
    Graybill JR, Sobel J, Saag M, et al.: Diagnosis and Management of Increased Intracranial Pressure in Patients with AIDS and Cryptococcal Meningitis. Clin Infect Dis 2000, 30:47–54. This important study highlights the fact that high opening pressure in the CSF (> 250 mm of H2O) at the time of diagnosis of cryptococcal meningitis is associated with more advanced disease, and an increased risk of death. Further, a reduction in opening pressure during treatment is associated with clinical response. The authors recommend large volume drainage for all patients with high opening pressures.PubMedCrossRefGoogle Scholar
  34. 34.
    Mylonakis E, Merriman NA, Rich JD, et al.: Use of cerebrospinal fluid shunt for the management of elevated intracranial pressure in a patient with active AIDS-related cryptococcal meningitis. Diagn Microbiol Infect Dis 1999, 34:111–114.PubMedCrossRefGoogle Scholar
  35. 35.
    Powderly WG, Saag MS, Cloud GA, et al.: A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992, 326:793–798.PubMedCrossRefGoogle Scholar
  36. 36.
    Brandt ME, Pfaller MA, Hajjeh R, et al.: Molecular subtypes and antifungal susceptibilities of serial cryptococcus neoformans isolates in human immunodeficiency virus infected patients. J Infect Dis 1996, 174:812–820.PubMedGoogle Scholar
  37. 37.
    Witt MD, Lewis RJ, Larsen RA, et al.: Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. Clin Infect Dis 1996, 22:322–328.PubMedGoogle Scholar
  38. 38.
    Powderly WG, Finkelstein D, Feinberg J, et al.: A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficency virus infection. N Engl J Med 1995, 332:700–705.PubMedCrossRefGoogle Scholar
  39. 39.
    Havlir DV, Dube MP, McCutchan JA, et al.: Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin Infect Dis 1998, 27:1369–1375.PubMedGoogle Scholar
  40. 40.
    Singh N, Barnish MJ, Berman S, et al.: Low-dose fluconazole as primary prophylaxis for cryptococcal infection in AIDS patients with CD4 cell counts of < or = 100/mm3: demonstration of efficacy in a positive, multicenter trial. Clin Infect Dis 1996, 23:1282–1286.PubMedGoogle Scholar
  41. 41.
    McKinsey DS, Wheat LJ, Cloud GA, et al.: Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebocontrolled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999, 28:1049–1056. Itraconazole effectively prevented both histoplasmosis and cryptococcosis in this study, and could be regarded as the preferred prophylactic agent for anti-fungal prophyaxis in patients living in the endemic area.PubMedGoogle Scholar
  42. 42.
    USPHS/IDSA Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR 1999, 48(RR10):1–59.Google Scholar
  43. 43.
    Race EM, Adelson-Mitty J, Kriegel GR, et al.: Focal mycobactrial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998, 351:252–255.PubMedCrossRefGoogle Scholar
  44. 44.
    Blanche P, Gombert B, Ginsburg C, et al.: HIV combination therapy: immune restitution causing cryptococcal lymphadenitis dramatically improved by anti-inflammatory therapy. Scand J Infect Dis 1998, 30:615–616.PubMedCrossRefGoogle Scholar
  45. 45.
    Woods ML 2nd, MacGinley R, Eisen DP, Allworth AM: HIV combination therapy: partial immune restitution unmasking latent cryptococcal infection. AIDS 1998, 12:1491–1494.PubMedCrossRefGoogle Scholar
  46. 46.
    Lanzafame M, Trevenzoli M, Carretta G, et al.: Mediastinal lymphadenitis due to cryptococcal infection in HIV-positive patients on highly active antiretroviral therapy. Chest 1999, 116:848–849.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2000

Authors and Affiliations

  • William G. Powderly
    • 1
  1. 1.Division of Infectious DiseasesWashington University School of MedicineSt. LouisUSA

Personalised recommendations